Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.46M | 4.50M | 8.91M | 9.01M | 19.24M |
| Total Other Revenue | 2.18M | 2.20M | 2.63M | 2.66M | 2.64M |
| Total Revenue | 6.64M | 6.70M | 11.54M | 11.67M | 21.88M |
| Cost of Revenue | 15.65M | 15.78M | 13.23M | 13.37M | 17.12M |
| Gross Profit | -9.00M | -9.08M | -1.68M | -1.70M | 4.76M |
| SG&A Expenses | 5.16M | 5.20M | 4.92M | 4.98M | 4.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.80M | 20.98M | 18.15M | 18.35M | 22.09M |
| Operating Income | -14.16M | -14.28M | -6.60M | -6.68M | -217.20K |
| Income Before Tax | -13.33M | -13.44M | -5.00M | -5.05M | 935.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.33M | -13.44M | -5.00M | -5.05M | 935.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.33M | -13.44M | -5.00M | -5.05M | 935.00K |
| EBIT | -14.16M | -14.28M | -6.60M | -6.68M | -217.20K |
| EBITDA | -13.76M | -13.88M | -5.60M | -5.66M | 1.53M |
| EPS Basic | -0.16 | -0.17 | -0.06 | -0.06 | 0.01 |
| Normalized Basic EPS | -0.10 | -0.10 | -0.04 | -0.04 | 0.01 |
| EPS Diluted | -0.17 | -0.17 | -0.06 | -0.06 | 0.01 |
| Normalized Diluted EPS | -0.10 | -0.10 | -0.04 | -0.04 | 0.01 |
| Average Basic Shares Outstanding | 80.87M | 80.87M | 80.59M | 80.59M | 80.32M |
| Average Diluted Shares Outstanding | 80.87M | 80.87M | 80.59M | 80.59M | 85.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |